RxDoctor Payments Data

Susan Weiss

Family · Brooklyn, NYNPI 1073680690

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 69.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $8,431 and has fallen 85.4% since, to $1,234 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,157in general payments, 2019–2025

Across 259 payments — averaging $85.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$15K
  • Gilead$3K
  • Merck$2K
  • Johnson & Johnson$705
  • Theratechnologies Inc.$496
  • Janssen Scientific Affairs, LLC$351
  • plus $351 from 3 others

What the payments were for

  • Consulting fees$9,53343%
  • Travel & lodging$2,27710%
  • Food & beverage$10,23846%
  • Education$1100%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,157 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala301$1,162,862
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$140,077
OdefseyEmtricitab/Rilpiviri/Tenof Ala37$128,420
TivicayDolutegravir Sodium49$103,072
TriumeqAbacavir/Dolutegravir/Lamivudi27$99,679
JulucaDolutegravir/Rilpivirine29$98,264
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$70,341
DescovyEmtricitabine/Tenofov Alafenam31$63,834
PifeltroDoravirine25$42,186
PrezcobixDarunavir/Cobicistat13$29,485
JanuviaSitagliptin Phosphate43$27,978
JardianceEmpagliflozin32$21,016
EliquisApixaban26$14,805
XareltoRivaroxaban13$7,246
Janumet XrSitagliptin Phos/Metformin Hcl13$6,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$3,312$1,366,773369 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca$15,320$301,014105 claims
MerckPifeltro, Januvia, Janumet Xr$1,624$77,11081 claims
Janssen Products, LPSymtuza$228$70,34116 claims
Johnson & JohnsonPrezcobix, Xarelto$705$36,73226 claims
PfizerEliquis$31$14,80526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →